Yang Y, et al. - Experts aimed to gauge the linaclotide's efficacy and safety in irritable bowel syndrome with constipation (IBS-C) patients in China and other regions. Co-primary and secondary endpoints were examined via a predefined three-step serial gatekeeping multiple comparisons procedure. A notable improvement was yielded in the spontaneous bowel movement/complete spontaneous bowel movement frequency, stool consistency, straining, abdominal pain, abdominal discomfort, and abdominal bloating through linaclotide vs placebo. The inference drawn was that once-daily 290 μg linaclotide improved bowel habits, abdominal symptoms, and global measures in a predominantly Chinese IBS-C population.